Sign up to save your podcasts
Or
Share Episode 421: 428. Asthma and Stroke --- A breathless combination
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Episode 421: 428. Asthma and Stroke --- A breathless combination
Minocycline in Acute Ischemic Stroke (EMPHASIS trial)
A multicenter, double-blind RCT in China studied 1,724 patients with acute ischemic stroke treated within 72 hours of onset. Patients received either a 4.5-day course of oral minocycline or placebo. Minocycline works by inhibiting microglial activation, which contributes to post-stroke inflammation.
Primary outcome: 52.6% of minocycline patients vs. 47.4% of placebo patients achieved good functional recovery (mRS 0–1) at 90 days (p=0.0061).
Safety: No difference in adverse events.
Practice impact: Clinicians are cautiously optimistic; further positive trials could lead to selective use of minocycline in AIS patients.
2. Tenecteplase for Basilar Artery Stroke (TRACE-5 trial)
This phase 3 RCT in China tested IV tenecteplase given within 24 hours of ischemic basilar artery occlusion against standard medical care (both groups could undergo thrombectomy).
Results: At 90 days, 38% of tenecteplase patients vs. 29% of controls had no or minimal disability (mRS 0–1 or baseline).
Safety: Similar rates of intracranial hemorrhage (2–3%) and mortality (29–31%).
Practice impact: Promising expansion of the thrombolytic window for severe posterior strokes; more evidence needed before routine use outside research settings.
View all episodes
By Questioning Medicine
4.9
7474 ratings
Minocycline in Acute Ischemic Stroke (EMPHASIS trial)
A multicenter, double-blind RCT in China studied 1,724 patients with acute ischemic stroke treated within 72 hours of onset. Patients received either a 4.5-day course of oral minocycline or placebo. Minocycline works by inhibiting microglial activation, which contributes to post-stroke inflammation.
Primary outcome: 52.6% of minocycline patients vs. 47.4% of placebo patients achieved good functional recovery (mRS 0–1) at 90 days (p=0.0061).
Safety: No difference in adverse events.
Practice impact: Clinicians are cautiously optimistic; further positive trials could lead to selective use of minocycline in AIS patients.
2. Tenecteplase for Basilar Artery Stroke (TRACE-5 trial)
This phase 3 RCT in China tested IV tenecteplase given within 24 hours of ischemic basilar artery occlusion against standard medical care (both groups could undergo thrombectomy).
Results: At 90 days, 38% of tenecteplase patients vs. 29% of controls had no or minimal disability (mRS 0–1 or baseline).
Safety: Similar rates of intracranial hemorrhage (2–3%) and mortality (29–31%).
Practice impact: Promising expansion of the thrombolytic window for severe posterior strokes; more evidence needed before routine use outside research settings.
More shows like Questioning Medicine
View all
Global News Podcast
7,639 Listeners
Sawbones: A Marital Tour of Misguided Medicine
14,841 Listeners
JAMA Editors' Summary
135 Listeners
AFP: American Family Physician Podcast
705 Listeners
JAMA Clinical Reviews
506 Listeners
Frankly Speaking About Family Medicine
265 Listeners
White Coat Investor Podcast
2,446 Listeners
The Curbsiders Internal Medicine Podcast
3,360 Listeners
Up First from NPR
56,508 Listeners
Core IM | Internal Medicine Podcast
1,152 Listeners
The Matt Walsh Show
28,325 Listeners
Consider This from NPR
6,381 Listeners
The Curious Clinicians
373 Listeners
Huberman Lab
29,207 Listeners
The Checkup with Doctor Mike
1,360 Listeners